Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00003245
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
15 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with recurrent or refractory non-Hodgkin's lymphoma.

Key Dates

Start date
Feb 18, 1998
Status verified
Nov 2018
Primary completion
Jul 30, 2004
Completion
Jul 30, 2004

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas - MD Anderson Cancer CenterHoustonTexas77030-4009-

Find similar trials in Houston, TX

By research site
University of Texas - MD Anderson Cancer Center· Houston, TX

Related Studies